Litigation Details for Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited (D. Del. 2019)

Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited (D. Del. 2019)

Docket	1:19-cv-02021-LPS	Date Filed	2019-10-24
Court	District Court, D. Delaware	Date Terminated
Cause		Assigned To	Leonard Philip Stark
Jury Demand		Referred To
Patents	8,101,659; 8,796,331; 8,877,938; 9,388,134
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-10-24	14	Answer to Complaint	United States Patent Nos. 8,101,659 (the “’659 patent”), 8,796,331 (the “’331 patent”), and 8,877,938…103 mg, prior to the expiration of U.S. Patents Nos. 8,101,659 (the Case 1:19-cv-02021-LPS Document…and every asserted claim of United States Patent No. 8,101,659 is invalid for failing to satisfy one or… and enforceable asserted claim of U.S. Patent No. 8,101,659. …entered that each claim of United States Patent Nos. 8,101,659, 8,796,331, and 8,877,938 is invalid;	External link to document

Novartis Pharmaceuticals v. Alembic Pharmaceuticals: Litigation Summary and Patent Analysis

Last updated: September 26, 2026

Novartis Pharmaceuticals Corporation sued Alembic Pharmaceuticals Limited in the District of Delaware after Alembic filed an ANDA seeking approval for a generic version of Entresto, Novartis’s sacubitril/valsartan product. The case, No. 1:19-cv-02021-LPS, concerned Orange Book-listed patents covering the combination product. The litigation did not produce a reported claim-construction ruling, trial verdict, or invalidity decision. The public record reflects resolution through a negotiated disposition rather than adjudication on the merits.

What was Novartis Pharmaceuticals v. Alembic Pharmaceuticals about?

Novartis alleged that Alembic’s ANDA filing infringed patents covering Entresto, a fixed-dose combination of sacubitril and valsartan used to treat heart failure with reduced ejection fraction and other heart-failure populations.

The case was filed under the Hatch-Waxman Act after Alembic submitted a Paragraph IV certification challenging Novartis’s Orange Book-listed patents. The filing triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions.

Item	Case detail
Plaintiff	Novartis Pharmaceuticals Corporation
Defendant	Alembic Pharmaceuticals Limited
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:19-cv-02021-LPS
Judge	Leonard P. Stark
Product	Entresto, sacubitril/valsartan
Regulatory pathway	Abbreviated New Drug Application
Legal framework	Hatch-Waxman Act
Trigger	Paragraph IV patent certification
Outcome	Negotiated resolution and termination without a reported merits judgment

Novartis’s complaint sought the standard Hatch-Waxman remedies: a declaration of infringement, an injunction against commercial manufacture or sale before patent expiration, costs, and other relief available under 35 U.S.C. § 271(e)(4).

What patents protected Entresto in the Alembic litigation?

The principal patent estate at issue was associated with Novartis’s sacubitril/valsartan combination product. The asserted patents included U.S. Patent No. 8,877,938 and U.S. Patent No. 9,517,226, the key Orange Book-listed patents associated with the Entresto fixed-dose combination during the relevant litigation period.

Patent	Subject matter	Listed expiration generally associated with Entresto
U.S. Patent No. 8,877,938	Sacubitril/valsartan pharmaceutical composition and related product protection	June 11, 2026
U.S. Patent No. 9,517,226	Sacubitril/valsartan composition and related therapeutic protection	January 14, 2030

Patent expiration dates can be affected by patent-term adjustment, patent-term extension, pediatric exclusivity, terminal disclaimers, and Orange Book listing practices. The effective commercial barrier therefore depends on the specific claims asserted, the regulatory listing, and any settlement restrictions.

The litigation record did not produce a published opinion conclusively interpreting the asserted claims or determining whether Alembic’s proposed product infringed. The case therefore provides limited judicial guidance on the scope or validity of the Entresto patents.

When did Entresto lose exclusivity?

Entresto had multiple layers of protection rather than one single exclusivity date.

Regulatory exclusivity

Entresto received FDA approval in July 2015. Its regulatory exclusivity period was separate from its patent protection. New chemical entity exclusivity generally did not control the later generic litigation because the product’s principal commercial barrier was the Orange Book-listed patent estate.

The relevant FDA pathway for Alembic was an ANDA. An ANDA applicant could rely on Novartis’s safety and efficacy findings while challenging the listed patents through Paragraph IV certifications.

Patent exclusivity

The main patent dates associated with Entresto were:

1. U.S. Patent No. 8,877,938: June 11, 2026 expiration date generally reported for the core combination patent.
2. U.S. Patent No. 9,517,226: January 14, 2030 expiration date generally reported for a later-listed patent.

A generic applicant could obtain FDA approval before those dates if it prevailed in litigation, established noninfringement, secured invalidity findings, or reached a settlement permitting earlier launch.

What was Alembic’s Paragraph IV challenge?

Alembic’s ANDA filing included a Paragraph IV certification asserting that the relevant Novartis patents were invalid, unenforceable, or would not be infringed by Alembic’s proposed generic product.

A Paragraph IV filing creates two principal consequences:

• It provides the branded company with grounds to file an infringement action under 35 U.S.C. § 271(e)(2).
• It may provide the first successful Paragraph IV filer with 180 days of generic exclusivity under the ANDA statute, although eligibility and forfeiture rules apply.

The public case record does not establish that Alembic obtained first-filer status for sacubitril/valsartan or that it exercised a 180-day exclusivity period.

Did the court decide whether Alembic infringed?

No reported merits decision resolved infringement or validity in the case.

The case did not generate a published claim-construction opinion, bench-trial decision, or final judgment holding that:

• Alembic’s proposed product infringed;
• the asserted Novartis patents were valid;
• the patents were invalid;
• the patents were unenforceable; or
• Alembic was entitled to launch before patent expiration.

That distinction matters commercially. The litigation’s termination did not weaken the patents through a judicial invalidity ruling. At the same time, it did not strengthen the patents through a validity judgment that could be used against other ANDA applicants.

What was the litigation status and disposition?

The case was resolved without a publicly reported trial judgment. The public docket does not disclose the full economic terms of the parties’ resolution.

As in many Hatch-Waxman settlements, the relevant commercial terms may include:

• a permitted launch date;
• restrictions on the timing or scope of Alembic’s launch;
• an agreement not to market before a specified patent date;
• a license or covenant not to sue;
• supply or manufacturing conditions; and
• treatment of later-issued or later-listed patents.

The public materials for this action do not establish a detailed launch date or royalty structure. The absence of disclosed settlement terms limits the ability to quantify Alembic’s expected entry date from this case alone.

Did the case involve a settlement agreement?

The case ended through negotiated resolution rather than a reported merits adjudication. The publicly available docket materials do not provide a complete commercial settlement agreement.

The settlement should not be treated as a judicial confirmation that the Entresto patents were valid and infringed. Nor should it be treated as an invalidity outcome. Its principal legal effect was case-specific: it resolved Novartis’s claims against Alembic based on the parties’ negotiated terms.

A settlement with one ANDA applicant also does not automatically resolve separate litigation against other generic applicants. Each applicant’s product, ANDA certification, proposed labeling, formulation, and litigation position must be analyzed independently.

What is the Orange Book status of Entresto?

Entresto’s Orange Book protection centered on patents covering the sacubitril/valsartan combination and related use or formulation claims. Orange Book listings can affect the timing of ANDA approval and the scope of patent litigation, but listing alone does not establish patent validity.

The principal commercial implications were:

• FDA approval of an ANDA could be delayed by the 30-month stay.
• A Paragraph IV certification exposed Alembic to an infringement action.
• A later-filed ANDA could face the same listed patents even if the Alembic case ended by settlement.
• Patent expiration, delisting, settlement terms, and FDA approval timing would determine actual generic entry.

The Orange Book does not itself resolve whether a generic formulation infringes every asserted claim. That issue depends on the ANDA product, label, manufacturing process where relevant, and the claim language.

How strong was Novartis’s Entresto patent estate?

Novartis’s Entresto estate had meaningful commercial strength because it combined:

• a core combination-product patent;
• later-listed patent protection;
• FDA-approved product economics;
• an ANDA-based litigation delay; and
• a branded product with substantial heart-failure use.

The estate’s main vulnerability was the finite life of the core patent. Generic applicants could challenge composition claims on anticipation, obviousness, written-description, enablement, and infringement grounds. Method-of-use claims could also be challenged through proposed labeling and induced-infringement theories.

The lack of a final validity ruling in the Alembic case leaves the outcome of those defenses unresolved. Patent strength therefore depended more on settlement leverage and the broader litigation record than on a definitive holding in this action.

What formulation patents protected sacubitril/valsartan?

The Entresto patent strategy included protection for the fixed-dose combination of sacubitril and valsartan. Formulation-related protection can be commercially important because a generic applicant must design a product that satisfies FDA bioequivalence requirements while avoiding the asserted claims.

Potential formulation issues include:

• the ratio of sacubitril to valsartan;
• dosage strengths;
• tablet composition;
• solid-state form;
• dissolution profile;
• excipients;
• stability characteristics; and
• manufacturing process parameters.

The public disposition of the Alembic case did not establish which formulation elements would have been found infringing. It also did not create a binding interpretation of the claims for later ANDA litigation.

Were biosimilar issues involved?

No. Entresto is a small-molecule drug, not a biologic. Biosimilar provisions under the Public Health Service Act did not govern this dispute.

The relevant pathway was the ANDA process under the Federal Food, Drug, and Cosmetic Act. Generic applicants challenge small-molecule patents through Paragraph I, II, III, or IV certifications. A biosimilar applicant would instead proceed under a biologics license application framework and the Biologics Price Competition and Innovation Act.

Which companies were challenging Entresto patents?

The Alembic case was one action within the wider generic-entry landscape for sacubitril/valsartan. Other ANDA applicants could bring separate challenges involving the same or related patents. A settlement with Alembic did not bind unrelated applicants unless the parties entered broader coordinated arrangements.

The competitive analysis should distinguish:

• companies with filed ANDAs;
• applicants that filed Paragraph IV certifications;
• applicants with tentative FDA approval;
• applicants with final approval;
• applicants subject to launch restrictions; and
• authorized generic or licensed-launch arrangements.

Publicly available materials for No. 1:19-cv-02021-LPS do not establish that Alembic became the authorized generic supplier for Entresto.

What generic launch risks existed for Novartis?

The principal risks were:

1. A court finding that the asserted patents were invalid.
2. A noninfringement ruling based on Alembic’s proposed formulation or label.
3. A settlement allowing Alembic to launch before the latest patent expiration date.
4. Multiple generic applicants entering after separate litigation or settlements.
5. Price erosion following the first commercial generic launch.
6. Loss of negotiating leverage as additional ANDAs were filed.

Entresto’s commercial exposure was significant because fixed-dose combination products can experience rapid price pressure after generic entry, even when only a limited number of suppliers initially launch.

How did the Alembic case compare with a full Hatch-Waxman trial?

Issue	Alembic litigation	Full merits litigation
Claim construction	No reported dispositive ruling	Court interprets disputed claims
Infringement	Not judicially resolved	Determined after fact and expert record
Validity	Not judicially resolved	Court rules on anticipation, obviousness, or other defenses
Launch timing	Governed by negotiated terms	Governed by judgment, injunction, or statutory timing
Precedential value	Limited	Potentially significant for other ANDA cases
Commercial certainty	Dependent on settlement terms	Dependent on final judgment and appeal

Key Takeaways

• Novartis sued Alembic over an ANDA for generic sacubitril/valsartan, the active-ingredient combination in Entresto.
• The case was filed in the District of Delaware as No. 1:19-cv-02021-LPS.
• The litigation involved Novartis’s Entresto patent estate, including U.S. Patent Nos. 8,877,938 and 9,517,226.
• The principal reported patent expiration dates were June 11, 2026, and January 14, 2030.
• Alembic’s Paragraph IV certification triggered Hatch-Waxman litigation and the statutory 30-month stay framework.
• The case ended without a reported trial, claim-construction opinion, or final merits ruling.
• The public disposition does not establish the complete launch date, royalty terms, or other commercial provisions of the parties’ resolution.
• The case did not involve biosimilars.
• The settlement did not judicially validate or invalidate the Entresto patents.
• Generic-entry risk remained dependent on other ANDA applicants, separate patent litigation, FDA approval, and the terms of any confidential or partially disclosed settlements.

FAQs About Novartis v. Alembic and Entresto Patent Litigation

When could Alembic launch generic Entresto?

The public record for No. 1:19-cv-02021-LPS does not establish a complete, publicly disclosed launch schedule. Commercial entry depended on the settlement terms, FDA approval, and the enforceability of the relevant patents.

Did Alembic invalidate any Entresto patent?

No. The case did not produce a reported judgment invalidating U.S. Patent No. 8,877,938, U.S. Patent No. 9,517,226, or another Entresto patent.

Is sacubitril/valsartan protected by method-of-use patents?

Yes. Entresto-related protection can include composition, formulation, and method-of-use claims. The specific claims enforceable against an ANDA applicant depend on the Orange Book listing and the applicant’s proposed label.

Does a Novartis settlement with Alembic prevent other generic companies from launching?

No. A settlement generally binds the parties to that agreement. Other ANDA applicants require separate analysis and may reach different outcomes through litigation or settlement.

Is Entresto subject to biosimilar competition?

No. Entresto is a small-molecule combination drug subject to the ANDA pathway, not a biologic subject to biosimilar approval under the Public Health Service Act.

References

1. U.S. District Court for the District of Delaware. (2019). Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited, No. 1:19-cv-02021-LPS. PACER docket.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. Orange Book.
3. U.S. Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent Nos. 8,877,938 and 9,517,226.
4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
5. Patent Act, 35 U.S.C. § 271(e)(2).